December 26, 2014 5:22 AM ET

Healthcare Equipment and Supplies

Company Overview of Cohera Medical, Inc.

Company Overview

Cohera Medical, Inc., doing business as Cohera Biomedical Adhesives, Inc., develops absorbable surgical adhesives and sealants for surgical procedures, applications, and specialties. It offers synthetic adhesives and sealants (to facilitate natural healing processes), and component adhesives (for hernia mesh fixations). The company also provides ordering services in Germany. It serves clinicians and surgeons. The company was founded in 2003 and is based in Pittsburgh, Pennsylvania.

209 Sandusky Street

Pittsburgh, PA 15212

United States

Founded in 2003





Key Executives for Cohera Medical, Inc.

Chief Executive Officer
Co-Founder and Member of Clinical Advisory Board
Co-Founder and Member of Clinical Advisory Board
Chief Financial Officer and Vice President of Finance
Chief Scientific Officer and Vice President of Research & Development
Compensation as of Fiscal Year 2014.

Cohera Medical, Inc. Key Developments

Cohera Medical, Inc. Receives Approval to Extend Shelf Life of for TissuGlu Surgical Adhesive in Europe

Cohera Medical, Inc. announced that it received approval from The British Standards Institution (BSI), to extend the shelf life of its TissuGlu Surgical Adhesive in the Europe from 7 to 18 months. The shelf life extension was granted based on modifications to product packaging only, and did not require any changes to the adhesive or applicator. The extended shelf life applies to all TissuGlu product being marketed in the Europe. Cohera Medical will begin immediately producing the TissuGlu product in the new packaging, and will begin shipping product in this configuration with the next lot of product produced. TissuGlu is targeted for use in large flap surgery procedures where pockets are created between planes of soft tissue. The adhesive is designed to hold the planes together during the healing process, in many cases eliminating the need for surgical drains, which are associated with discomfort, greater risk of infection, and longer hospital stays. The recently completed U.S. clinical trial showed the elimination of drains in 73% of abdominoplasty patients using TissuGlu, with no additional measures needed to address fluid ccumulation. There are approximately 1M US-based large flap procedures per year, growing at an annual rate of 4.8% that could utilize TissuGlu. The product has been on the market in the EU since 2011, and currently more than 1,500 procedures have been conducted with TissuGlu bringing great benefit to patients, surgeons, and caregivers.

Cohera Medical, Inc. Appoints Richard W. Pascoe to Its Board of Directors

Cohera Medical, Inc. announced the appointment of Richard W. Pascoe as a member of the company's Board of Directors. Mr. Pascoe is currently the Chief Executive Officer of Apricus Biosciences, Inc. Mr. Pascoe joined Apricus in March of 2013 following the merger of Somaxon Pharmaceuticals with Pernix. At Somaxon Mr. Pascoe held the role of Chief Executive Officer and was responsible for the FDA approval of Somaxon's lead drug Silenor.

Cohera Medical, Inc. Applies for CE Mark Approval for Sylys Surgical Sealant

Cohera Medical, Inc. announced that it has applied for CE Mark approval for Sylys(R) Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks in gastrointestinal procedures. CE Mark approval, expected by the end of 2014 based on this filing, will allow for marketing of the product in the European Union and other countries. Sylys is applied during gastrointestinal procedures to help prevent the occurrence of anastomotic leaks -- a serious complication that occurs in up to 23% of patients undergoing colorectal surgery. At least one-third of the post-surgical mortality after colorectal surgery is attributed to leaks, and survivors generally have protracted recoveries. The additional care required to manage this serious complication can cause up to a five-fold increase in patient management costs. Sylys is designed to help reduce anastomotic leakage in intestinal procedures by providing additional support during the first few days of healing, when the development of leaks is most likely to occur. The sealant is applied as a viscous fluid that cures rapidly to create a flexible, elastic seal over the anastomosis site. The market for Sylys is significant, with several hundred thousand procedures a year worldwide representing a multi-billion dollar opportunity. Due to the unmet clinical need, Sylys would represent a breakthrough in this market that will lead to improved patient outcomes as well as reduced patient management costs for healthcare providers.

Similar Private Companies By Industry

Company Name Region
Spectra Med, Inc. United States
R2T2 Laboratories Inc. United States
ThyroTec LLC United States
TREK Diagnostic Systems, Inc. United States
Avalon Holding Group, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cohera Medical, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at